[HTML][HTML] Vascular tissue engineering: progress, challenges, and clinical promise
Although the clinical demand for bioengineered blood vessels continues to rise, current
options for vascular conduits remain limited. The synergistic combination of emerging …
options for vascular conduits remain limited. The synergistic combination of emerging …
[HTML][HTML] Vascular Tissue Engineering: Progress, Challenges, and Clinical Promise
HHG Song, RT Rumma, CK Ozaki, ER Edelman… - Cell Stem Cell, 2018 - Elsevier
Although the clinical demand for bioengineered blood vessels continues to rise, current
options for vascular conduits remain limited. The synergistic combination of emerging …
options for vascular conduits remain limited. The synergistic combination of emerging …
[引用][C] Vascular Tissue Engineering: Progress, Challenges, and Clinical Promise
HHG Song, RT Rumma, CK Ozaki, ER Edelman… - Cell Stem Cell, 2018 - cir.nii.ac.jp
Vascular Tissue Engineering: Progress, Challenges, and Clinical Promise | CiNii Research
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
Vascular Tissue Engineering: Progress, Challenges, and Clinical Promise.
HG Song, RT Rumma, CK Ozaki, ER Edelman… - Cell Stem …, 2018 - europepmc.org
Although the clinical demand for bioengineered blood vessels continues to rise, current
options for vascular conduits remain limited. The synergistic combination of emerging …
options for vascular conduits remain limited. The synergistic combination of emerging …
[HTML][HTML] Vascular tissue engineering: progress, challenges, and clinical promise
HHG Song, RT Rumma, CK Ozaki, ER Edelman… - Cell stem …, 2018 - ncbi.nlm.nih.gov
Although the clinical demand for bioengineered blood vessels continues to rise, current
options for vascular conduits remain limited. The synergistic combination of emerging …
options for vascular conduits remain limited. The synergistic combination of emerging …
Vascular Tissue Engineering: Progress, Challenges, and Clinical Promise
HH Song, RT Rumma, ER Edelman - 2018 - dspace.mit.edu
Although the clinical demand for bioengineered blood vessels continues to rise, current
options for vascular conduits remain limited. The synergistic combination of emerging …
options for vascular conduits remain limited. The synergistic combination of emerging …
[HTML][HTML] Vascular Tissue Engineering: Progress, Challenges, and Clinical Promise
HHG Song, RT Rumma, CK Ozaki, ER Edelman… - Cell Stem Cell, 2018 - cell.com
Although the clinical demand for bioengineered blood vessels continues to rise, current
options for vascular conduits remain limited. The synergistic combination of emerging …
options for vascular conduits remain limited. The synergistic combination of emerging …
Vascular Tissue Engineering: Progress, Challenges, and Clinical Promise
HHG Song, RT Rumma, CK Ozaki… - Cell stem …, 2018 - pubmed.ncbi.nlm.nih.gov
Although the clinical demand for bioengineered blood vessels continues to rise, current
options for vascular conduits remain limited. The synergistic combination of emerging …
options for vascular conduits remain limited. The synergistic combination of emerging …
Vascular Tissue Engineering: Progress, Challenges, and Clinical Promise
HHG Song, RT Rumma, CK Ozaki… - Cell stem …, 2018 - pubmed.ncbi.nlm.nih.gov
Although the clinical demand for bioengineered blood vessels continues to rise, current
options for vascular conduits remain limited. The synergistic combination of emerging …
options for vascular conduits remain limited. The synergistic combination of emerging …
Vascular Tissue Engineering: Progress, Challenges, and Clinical Promise.
GS HH, RT Rumma, CK Ozaki, ER Edelman… - Cell Stem …, 2018 - europepmc.org
In the version of our Review published on March 1, 2018, we erroneously stated that certain
scaffolds created for an “off-the-shelf” graft were seeded with autologous endothelium. We …
scaffolds created for an “off-the-shelf” graft were seeded with autologous endothelium. We …